Advertisements



Lineage Cell Therapeutics conducts sale of shares in OncoCyte

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 11th, 2019

Lineage Cell says not planning to conduct additional sales of OncoCyte in NT

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 11th, 2019

Lineage Cell Therapeutics (LCTX ) Presents At H.C. Wainwright 21st Annual Global Investment Conference - Slideshow

Lineage Cell Therapeutics (LCTX ) Presents At H.C. Wainwright 21st Annual Global Investment Conference - Slideshow.....»»

Category: topSource: seekingalphaSep 10th, 2019

Lineage Cell Therapeutics issued U.S. patent

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 4th, 2019

Lineage Cell Therapeutics announces publication of stem cells paper

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 3rd, 2019

Lineage Cell Therapeutics announces issuance of patent from USPTO

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 26th, 2019

Good News for Stem Cell Transplants

Akari Therapeutics shares jumped on Wednesday after the firm announced that the FDA has granted Fast Track designation for its stem cell transplant treatment......»»

Category: blogSource: 247wallstAug 14th, 2019

BioTime launches new corporate brand, changes name to Lineage Cell Therapeutics

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 31st, 2019

BioTime sale of OncoCyte shares expands shareholder base, says Benchmark

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 3rd, 2019

Meet One of ASCO’s First Losers

Turning Point Therapeutics shares dipped on Friday after the firm posted interim data for its midstage study in ROS1-positive non-small cell lung cancer patients......»»

Category: blogSource: 247wallstMay 31st, 2019

Crispr, Vertex shares fall after FDA halts sickle-cell disease trial

Crispr Therapeutics and Vertex Pharmaceuticals Inc. said late We.....»»

Category: topSource: marketwatchMay 30th, 2018

3 Possible Outcomes From The Clinical Hold On Crispr Therapeutics"s Sickle Cell Candidate

Shares of Crispr Therapeutics AG (NASDAQ: CRSP) fell more than 7 percent Thursday morning after the U.S. Food and Drug Administration said it placed a clinical hold on the company's therapy. Latest Ratings for CRSP DateFir.....»»

Category: blogSource: benzingaMay 31st, 2018

Global Blood Therapeutics Shares Plunge After Sickle Cell Candidate Shows Reduced Effect

Global Blood Therapeutics Inc (NASDAQ: GBT) shares were sliding Friday after the release of updated data for the company's sickle cell disease candidate that will be present read more.....»»

Category: blogSource: benzingaJun 15th, 2018

Global Blood Therapeutics shares drop after late-stage data for sickle cell disease treatment

Global Blood Therapeutics Inc. shares dropped as much as 12% in premarket trade on Wednesday after the company reported results for a late-stage trial of sickle cell disease therapy, and said that it met with the U.S. Food and Drug Ad.....»»

Category: topSource: marketwatchJun 27th, 2018

Global Blood Therapeutics Meets Primary Endpoints In Sickle Cell Study, Seeks Accelerated FDA Approval

Global Blood Therapeutics Inc (NASDAQ: GBT) shares were trading down off the open Wednesday after the company released data from its sickle cell disease candidate. read more.....»»

Category: blogSource: benzingaJun 27th, 2018

CRISPR Therapeutics Partners Up to Take on Diabetes

CRISPR Therapeutics shares dipped on Monday after the company announced a collaboration with ViaCyte focused on the discovery, development and commercialization of gene-edited allogeneic stem cell........»»

Category: blogSource: 247wallstSep 17th, 2018

Why Mirati Therapeutics Is Sinking

Mirati shares dropped on Monday after the company announced updated positive clinical data from its midstage study in non-small cell lung cancer......»»

Category: blogSource: 247wallstOct 22nd, 2018

Plug Power files to sell 21.2 million shares

Plug Power, the Latham, New York fuel cell manufacturer, plans to sell up to 21.2 million shares of common stock owned by two major shareholders. Plug is facilitating the sale and will sell the shares at a maximum price of $1.82, according to a pr.....»»

Category: topSource: bizjournalsNov 19th, 2018

Global Blood Therapeutics Wins Big With FDA Approval

Global Blood Therapeutics shares shot up on Monday after the company announced that it received an update from the FDA in regards to its sickle cell disease treatment......»»

Category: blogSource: 247wallstDec 3rd, 2018

Global Blood Therapeutics stock up 40% after FDA agrees to accelerated approval pathway for sickle cell disease drug

Shares of Global Blood Therapeutics Inc. shot up 40% Monday morn.....»»

Category: topSource: marketwatchDec 3rd, 2018

Global Blood"s Sickle Cell Disease Drug Snags Accelerated FDA Approval Pathway

Global Blood Therapeutics Inc (NASDAQ: GBT) shares are trading at a nearly three-month high, with a FDA event being the catalyst. Latest Ratings for GBT DateF.....»»

Category: blogSource: benzingaDec 3rd, 2018